Thromb Haemost 1996; 76(05): 675-678
DOI: 10.1055/s-0038-1650641
Original Article
Schattauer GmbH Stuttgart

Serum Thrombopoietin (TPO) Levels in Patients with Amegakaryocytic Thrombocytopenia Are much Higher than those with Immune Thrombocytopenic Purpura

Harumi Y Mukai
1   The Division of Hematology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
,
Hiroshi Kojima
1   The Division of Hematology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
,
Kazuo Todokoro
2   Tsukuba Life Science Center, The Institute of Physical and Chemical Research (Riken), Koyadai, Tsukuba, Ibaraki, Japan
,
Tomoyuki Tahara
3   Pharmaceutical Research Laboratory, Kirin Brewery Co., Ltd., Maebashi, Gunma, Japan
,
Takashi Kato
3   Pharmaceutical Research Laboratory, Kirin Brewery Co., Ltd., Maebashi, Gunma, Japan
,
Yuichi Hasegawa
1   The Division of Hematology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
,
Toshitaka Kobayashi
1   The Division of Hematology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
,
Haruhiko Ninomiya
1   The Division of Hematology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
,
Toshiro Nagasawa
1   The Division of Hematology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
,
Tsukasa Abe
1   The Division of Hematology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
› Author Affiliations
Further Information

Publication History

Received 14 February 1996

Accepted after resubmission 30 July 1996

Publication Date:
11 July 2018 (online)

Summary

We assayed serum thrombopoietin (TPO) levels in amegakaryocytic thrombocytopenia (AMT) and immune thrombocytopenic purpura (ITP) patients by using a newly established enzyme-linked immunosorbent assay (ELISA). TPO levels in AMT patients were quite high (mean ± SD = 13.7 ± 11.2 fmoles/ml, n = 4), whereas those in ITP patients were only slightly higher (1.25 ± 0.39, n = 12) than those of the healthy donors (0.55 ± 0.2, n = 20). Furthermore, in ITP patients no correlation was observed between platelet counts and serum TPO levels (correlation coefficient = 0.14). We further assayed serum TPO levels sequentially during steroid treatment in patients with AMT and ITP. In one AMT patient serum TPO levels started to decrease in accordance with the increase of megakaryocyte counts, which preceded the increase in platelet counts. However, in ITP patients serum TPO levels did not change significantly throughout the course of the treatment despite the recovery of platelet counts. Based on these findings, we conclude that serum TPO levels may be regulated at least in part by megakaryocyte counts.

 
  • References

  • 1 de Sauvage FJ, Hass PE, Spencer SD, Malloy BE, Gurney AL, Spencer SA, Darbonne WC, Henzel WJ, Wong SC, Kunang WJ, Oles KJ, Hultgren B, Solberg Jr LA, Goeddel DV, Eaton DL. Stimulation of megakaryopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994; 369: 533-538
  • 2 Lok S, Kaushansky K, Holly RD, Kuijper JL, Lofton-Day CE, Oort PJ, Grant FJ, Heipel MD, Burkhead SK, Kramer JM, Bell LA, Sprecher CA, Blumberg H, Johnson R, Pruncard D, Ching AFT, Mathewes SL, Bailey MC, Forstrom JW, Buddie MM, Osborn SG, Evans SJ, Sheppard PO, Pre-snell SR, O’Hara PJ, Hagen FS, Roth GJ, Foster DC. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vitro. Nature 1994; 369: 565-568
  • 3 Kaushansky K, Lok S, Holly RD, Broudy VC, Lin N, Bailey MC, Forstrom JW, Buddie MM, Oort PJ, Hagen FS, Roth GJ, Papayannopoulou T, Foster DC. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994; 369: 568-571
  • 4 Wendling FW, Maraskovsky E, Debili N, Florindo C, Teepe M, Titeux M, Methia N, Breton-Gorius J, Cosman D, Vainchenker W. c-Mpl ligand is a humoral regulator of megakaryocytopoiesis. Nature 1994; 369: 571-574
  • 5 Batley TD, Bogenberger PH, Hunt P, Li YS, Lu HS, Martin F, Chang MS, Samal B, Nichol JL, Swift S, Johnson MJ, Hsu RY, Parker VP, Suggs S, Skrine JD, Merewether LA, Clogston C, Hsu E, Hokom MM, Hornkohl A, Choi E, Pangelinan M, Sun Y, Mar V, McNinch J, Simonet L, Jacobsen F, Xie C, Shutter J, Chute H, Basu R, Selander L, Trollinger D, Sieu L, Padilla D, Trail G, Elliott G, Izumi R, Covey T, Crouse J, Garcia A, Xu W, Castillo JD, Biron J, Cole S, Hu CT, Pacifici R, Ponting I, Saris C, Wen D, Yung YP, Lin H. Bosselman RA. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 1994; 77: 1117-1124
  • 6 Broudy VC, Lin NL, Kaushansky K. Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood 1995; 85: 1719-1726
  • 7 Zeigler FC, de Sauvage F, Widmer HR, Keller GA, Donahue C, Schreiber RD, Malloy B, Hass P, Eaton D, Matthews W. In vitro megakaryocyto-poietic and thrombopoietic activity of c-mpl ligand (TPO) on purified murine hematopoietic stem cells. Blood 1994; 84: 4045-4052
  • 8 Choi ES, Nichol JL, Hokom MM, Hornkohl AC, Hunt P. Platelets generated in vitro from proplatelet-displaying human megakaryocytes are functional. Blood 1995; 85: 402-413
  • 9 Kaushansky K. Thrombopoietin: The primary regulator of platelet production. Blood 1995; 86: 419-431
  • 10 Drachman JG, Griffin JD, Kaushansky K. The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, She, and c-Mpl. J Biol Chem 1995; 270: 4979-4982
  • 11 Tortolani PJ, Johnston JA, Bacon CM, McVicar DW, Shimosato A, Linne-kin D, Longo DL, O’Shea J. Thrombopoietin induces tyrosine phosphorylation and activation of the Janus kinases, JAK2. Blood 1995; 85: 3444-3451
  • 12 Miyakawa Y, Oda A, Druker BJ, Kato T, Miyazaki H, Handa M, Ikeda Y. Recombinant thrombopoietin induces rapid protein tyrosine phosphorylation of Janus kinase 2 and She in human blood platelets. Blood 1995; 86: 23-27
  • 13 Kojima H, Hamazaki Y, Nagata Y, Todokoro K, Nagasawa T, Abe T. Modulation of platelet activation in vitro by thrombopoietin. Thromb Haemost 1995; 74: 1541-1545
  • 14 Kuter DJ, Rosenberg RD. Regulation of megakaryocyte ploidy in vitro in the rat. Blood 1990; 75: 74-81
  • 15 Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin: A physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci USA 1994; 91: 11104-11108
  • 16 Kuter DJ, Rosenberg RD. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood 1995; 85: 2720-2730
  • 17 Hunt P, Li YS, Nichol JL, Hokom MM, Jakob MB, Susan E, Swift F, Skrine JD, Alex CH, Hsieng L, Clogston C, Merewether LA, Johnson MJ, Parker V, Knudten A, Farese A, Hsu RY, Garcia A, Stead R, Bosselman RA, Bartley TD. Purification and biologic characterization of plasma-derived megakaryocyte growth and development factor. Blood 1995; 86: 540-547
  • 18 McCarty JM, Sprugel KH, Fox NE, Sabath DE, Kaushansky K. Murine thrombopoietin mRNA levels are modulated by platelet count. Blood 1995; 86: 3668-3675
  • 19 Fielder PJ, Gurney AL, Stefanich E, Marian M, Moore MW, Carver-Moore K, de Sauvage FJ. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood 1996; 87: 2154-2161
  • 20 Nagasawa T, Hasegawa Y, Kamoshita M, Ohtani K, Itoh T, Shinagawa A, Kojima H, Ninomiya H, Abe T. Megakaryopoiesis in patients with cyclic thrombocytopenia. Brit J Haematol 1995; 91: 185-190
  • 21 Tahara T, Usuki K, Sato H, Ohashi H, Morita H, Tsumura H, Matsumoto A, Miyazaki H, Urabe A, Kato T. A sensitive sandwich ELISA for measuring thrombopoietin in human serum: Serum thrombopoietin levels in healthy volunteers and in patients with hematopoietic disorder. Brit J Haematol 1996; 93: 783-788
  • 22 Nagasawa T, Sakurai T, Kashiwagi H, Abe T. Cell-mediated amegakaryo-cytic thrombocytopenia associated with systemic lupus erythematosus. Blood 1986; 67: 479-483
  • 23 Hoffman R, Bruno E, Elwell J, Mazur E, Gewirtz AM, Dekker P, Denes AE. Acquired amegakaryocytic thrombocytopenic purpura: A syndrome of diverse etiology. Blood 1982; 60: 1173-1178
  • 24 Guinan EC, Lee YS, Lopez KD, Kohler S, Oette DH, Bruno E, Kozakewich H, Nathan DG, Hoffman R. Effect of interleukin-3 and granulocyte-macro-phage colony-stimulating factor on thrombopoiesis in congenital amegakaryocytic thrombocytopenia. Blood 1993; 81: 1691-1698
  • 25 Hoffman R, Zaknoen S, Yang HH, Bruno E, LoBuglio AF, Arrowsmith JB, Prchal JT. An antibody cytotoxic to megakaryocyte progenitor cells in a patient with immune thrombocytopenic purpura. N Engl J Med 1985; 312: 1170-1174
  • 26 Hoffman R, Briddell RA, van Besien K, Srour EF, Guscar T, Hudson NW, Ganser A. Acquired cyclic amegakaryocytic thrombocytopenia associated with an immunoglobulin blocking the action of granulocyte-macrophage colony-stimulating factor. N Engl J Med 1989; 321: 97-102
  • 27 Gewirtz AM, Sacchetti MK, Bien R, Barry WE. Cell-mediated suppression of megakaryocytepoiesis in acquired amegakaryocytic thrombocytopenic purpura. Blood 1986; 68: 619-626
  • 28 Hoffman R, Mazur E, Bruno E, Floyd V. Assay of an activity in the serum of patients with disorders of thrombopoiesis that stimulates formation of megakaryocytic colonies. N Engl J Med 1981; 305: 533-538
  • 29 Emmons RVB, Shulman NR, Reid DM, Young NS, Meng YG, Lee WL, Cohen RL, Dunbar CE. Thrombocytopenic patients with aplastic anemia have high TPO levels whereas those with immune thrombocytopenia are much lower. Blood 1995; 10 (Suppl. 01) 372a-1475
  • 30 Bartocci A, Mastrogiannis DS, Migliorati G, Stockert RJ, Wolkoff AW, Stanley ER. Macrophages specifically regulate the concentration of their own growth factor in the circulation. Proc Natl Acad Sci USA 1987; 84: 6179-6184